7.4 days

MEDICAL: Lymphoma and Nonacute Leukemia with CC

Multiple myeloma, also known as plasma cell myeloma, malignant plasmacytoma, and myelo-matosis, is a type of cancer formed by malignant plasma cells (a mature, active B lymphocyte). It is the most common primary neoplasm of the skeletal system with an annual incidence in the United States of48,000. When a B lymphocyte is stimulated by a T cell, it develops into a mature, antibody-producing factory called a plasma cell. Multiple myeloma results from a transformed plasma cell that multiplies and produces antibody unceasingly, without stimulation. When plasma cells grow out of control, they generate tumors that infiltrate the bone marrow and other sites. Although multiple myeloma could be considered a lymphoma, it is generally classified differently and discussed separately because it presents a different profile of onset, symptoms, treatment, and prognosis.

The disease infiltrates none and produces osteolytic lesions throughout the skeleton, destroying bones. In later stages, multiple myeloma infiltrates the body organs and destroys them as well. About 3 to 20 years of plasma cell growth may pass before symptoms become apparent. When patients do report symptoms, the disease is well advanced. Survival rates depend on the stage of initial diagnosis (Table 2). The 5-year survival rate for stage I patients in about 50%,

• TABLE 2 Staging System For Multiple Myeloma

Multiple Myeloma DRG Category:

Mean LOS: Description:

• TABLE 2 Staging System For Multiple Myeloma

0 0

Post a comment